RxDoctor Payments Data

Vartouhi Mansourian

Psychiatric/Mental Health · Long Beach, CANPI 1013620483

Payments from drug & device makers

$2,991in general payments, 2019–2025

Across 190 payments — averaging $15.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$776
  • Alkermes, Inc.$452
  • Vanda Pharmaceuticals Inc.$249
  • Indivior Inc.$123
  • Neurocrine Biosciences, Inc.$106
  • plus $206 from 4 others

What the payments were for

  • Food & beverage$2,991100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,991 in reported general payments places this provider in the 85th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$331,950
Medicare patients
658
Services billed
4,873

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate18$129,102
RexultiBrexpiprazole42$56,185
Invega SustennaPaliperidone Palmitate20$48,824
VraylarCariprazine Hcl13$19,439
Aripiprazole133$13,905
Fluphenazine Hcl36$13,618
Olanzapine OdtOlanzapine120$11,981
Risperidone OdtRisperidone52$11,357
Divalproex Sodium235$8,339
Olanzapine348$6,026
Quetiapine Fumarate362$5,736
Buspirone Hcl300$4,414
Risperidone292$4,354
Haloperidol117$4,155
Mirtazapine269$3,486

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$106$129,10218 claims
Otsuka America Pharmaceutical, Inc.Rexulti$102$56,18542 claims
Johnson & JohnsonInvega Sustenna$1,079$48,82420 claims
AbbVieVraylar$27$19,43913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →